Preventive study in subjects at risk of fatal familial insomnia

Innovative approach to rare diseases

Gianluigi Forloni, Mauro Tettamanti, Ugo Lucca, Yasmin Albanese, Elena Quaglio, Roberto Chiesa, Alessandra Erbetta, Flavio Villani, Veronica Redaelli, Fabrizio Tagliavini, Vladimiro Artuso, Ignazio Roiter

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The text describes a preventive clinical trial with drug treatment in a very rare neurodegenerative disease (Fatal familial Insomnia, FFI) designed with the help of individuals at genetic risk of developing the disease, asymptomatic carriers, who have agreed to be exposed over a 10-year period to doxycycline, an antibiotic with anti-prion activity. At least 10 carriers of the FFI mutation over 42 y old will be treated with doxycycline (100 mg/die) and the incidence of the disease will be compared to that of an historical dataset. For ethical reasons a randomized, double-blind, placebo-controlled trial was not feasible, however the study design and the statistical analysis ensure the scientific value of the results. This approach might represent an important breakthrough in terms of potential therapy and knowledge of rare diseases that could give some hopes to these neglected patients.

Original languageEnglish
Pages (from-to)75-79
Number of pages5
JournalPrion
Volume9
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Fatal Familial Insomnia
Doxycycline
Rare Diseases
Asymptomatic Diseases
Prions
Neurodegenerative Diseases
Neurodegenerative diseases
Drug therapy
Placebos
Clinical Trials
Anti-Bacterial Agents
Mutation
Incidence
Statistical methods
Therapeutics
Pharmaceutical Preparations

Keywords

  • Doxycycline
  • Neurodegeneration
  • Preventive treatment in FFI
  • Prion’s diseases
  • Trial

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Infectious Diseases
  • Cellular and Molecular Neuroscience

Cite this

Preventive study in subjects at risk of fatal familial insomnia : Innovative approach to rare diseases. / Forloni, Gianluigi; Tettamanti, Mauro; Lucca, Ugo; Albanese, Yasmin; Quaglio, Elena; Chiesa, Roberto; Erbetta, Alessandra; Villani, Flavio; Redaelli, Veronica; Tagliavini, Fabrizio; Artuso, Vladimiro; Roiter, Ignazio.

In: Prion, Vol. 9, No. 2, 01.01.2015, p. 75-79.

Research output: Contribution to journalArticle

@article{3a150be5fbbb4ace843d224b70ee0694,
title = "Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases",
abstract = "The text describes a preventive clinical trial with drug treatment in a very rare neurodegenerative disease (Fatal familial Insomnia, FFI) designed with the help of individuals at genetic risk of developing the disease, asymptomatic carriers, who have agreed to be exposed over a 10-year period to doxycycline, an antibiotic with anti-prion activity. At least 10 carriers of the FFI mutation over 42 y old will be treated with doxycycline (100 mg/die) and the incidence of the disease will be compared to that of an historical dataset. For ethical reasons a randomized, double-blind, placebo-controlled trial was not feasible, however the study design and the statistical analysis ensure the scientific value of the results. This approach might represent an important breakthrough in terms of potential therapy and knowledge of rare diseases that could give some hopes to these neglected patients.",
keywords = "Doxycycline, Neurodegeneration, Preventive treatment in FFI, Prion’s diseases, Trial",
author = "Gianluigi Forloni and Mauro Tettamanti and Ugo Lucca and Yasmin Albanese and Elena Quaglio and Roberto Chiesa and Alessandra Erbetta and Flavio Villani and Veronica Redaelli and Fabrizio Tagliavini and Vladimiro Artuso and Ignazio Roiter",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/19336896.2015.1027857",
language = "English",
volume = "9",
pages = "75--79",
journal = "Prion",
issn = "1933-6896",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Preventive study in subjects at risk of fatal familial insomnia

T2 - Innovative approach to rare diseases

AU - Forloni, Gianluigi

AU - Tettamanti, Mauro

AU - Lucca, Ugo

AU - Albanese, Yasmin

AU - Quaglio, Elena

AU - Chiesa, Roberto

AU - Erbetta, Alessandra

AU - Villani, Flavio

AU - Redaelli, Veronica

AU - Tagliavini, Fabrizio

AU - Artuso, Vladimiro

AU - Roiter, Ignazio

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The text describes a preventive clinical trial with drug treatment in a very rare neurodegenerative disease (Fatal familial Insomnia, FFI) designed with the help of individuals at genetic risk of developing the disease, asymptomatic carriers, who have agreed to be exposed over a 10-year period to doxycycline, an antibiotic with anti-prion activity. At least 10 carriers of the FFI mutation over 42 y old will be treated with doxycycline (100 mg/die) and the incidence of the disease will be compared to that of an historical dataset. For ethical reasons a randomized, double-blind, placebo-controlled trial was not feasible, however the study design and the statistical analysis ensure the scientific value of the results. This approach might represent an important breakthrough in terms of potential therapy and knowledge of rare diseases that could give some hopes to these neglected patients.

AB - The text describes a preventive clinical trial with drug treatment in a very rare neurodegenerative disease (Fatal familial Insomnia, FFI) designed with the help of individuals at genetic risk of developing the disease, asymptomatic carriers, who have agreed to be exposed over a 10-year period to doxycycline, an antibiotic with anti-prion activity. At least 10 carriers of the FFI mutation over 42 y old will be treated with doxycycline (100 mg/die) and the incidence of the disease will be compared to that of an historical dataset. For ethical reasons a randomized, double-blind, placebo-controlled trial was not feasible, however the study design and the statistical analysis ensure the scientific value of the results. This approach might represent an important breakthrough in terms of potential therapy and knowledge of rare diseases that could give some hopes to these neglected patients.

KW - Doxycycline

KW - Neurodegeneration

KW - Preventive treatment in FFI

KW - Prion’s diseases

KW - Trial

UR - http://www.scopus.com/inward/record.url?scp=84944450004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944450004&partnerID=8YFLogxK

U2 - 10.1080/19336896.2015.1027857

DO - 10.1080/19336896.2015.1027857

M3 - Article

VL - 9

SP - 75

EP - 79

JO - Prion

JF - Prion

SN - 1933-6896

IS - 2

ER -